NYSE:SYK
Stryker Corp. (SYK)
330.25
+11.28 (3.54%)
as of Jul 24, 2026, 8:00:00 pm Market Open.
257 watching
Financials 
Technical Analysis 0
Investor Insights
Jul 26, 2026, 12:00 amThis summary was created by AI, based on 7 opinions in the last 12 months.
Stryker Corp (SYK) is recognized as a leader in orthopedic procedures, particularly in hips and knees, with expectations of regaining market share after a tough year linked to overall health sector weaknesses and a cybersecurity incident. While there is an acknowledgment of a broader weakness in the medtech industry, many experts highlight Stryker's strong relationships with healthcare professionals and its consistent market share gains from competitors like Johnson & Johnson. Analysts project long-term growth driven by an aging population and advancements in robotic-assisted surgeries, which are expected to significantly boost the company's orthopedics segment. Concerns remain about short-term performance, but the long-term outlook is generally optimistic, making Stryker an attractive investment based on its valuation and growth potential.
Consensus
Mixed
Valuation
Fair Value
Similar
ZBH
DON'T BUY
PAST TOP PICK
(A Top Pick Mar 16/22, Down 2%) Great business. Backlog in elective surgeries due to Covid will lead to good earnings growth going forward. Good growth internationally. Demographic play. Loyal customer base. Great medical device story.
Paul Harris, CFAOwned
biotechnologypharmaceutical
DON'T BUY
SYK vs. ISRG ISRG reported last night, market not too happy, but this is short term. At 50x PE, ISRG is expensive on any traditional valuation, yet has no real competition in robotic surgery market. ISRG has a great franchise and platform, and will grow earnings over next decade 200-300%. Because SYK is in hips and knees, it's not in direct competition. SYK's space is more competitive, but also has much lower valuation. With Covid shortages ending, SYK could see some upside next 3-4 months.
Jamie Murray No
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Nov 02/21, Down 19%) Good growth internationally. Demand increasing with aging population. Great balance sheet, opportunity to make acquisitions. Trades at 22x. Pandemic backlog of elective surgeries offsets inflationary costs. Supply chain difficulties persist. He'd buy here. Yield is 1.4%.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
Medical supply companies impacted by Covid-19, staffing shortages and inflation.
Need for healthcare services not going away.
Likes business area, but not investing in Stryker.
Other companies with better prospects.
Jamie Murray No
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Aug 24/21, Down 23%) It is a medical device company and had a tough time over Covid. Now there is a big backlog in elective surgeries so much more of its products will be needed. 71% of business is from the U.S. where there is lots of room to grow globally. Also doctors doing the surgeries tend to stay with the same products. Lots of free cash flow.
Paul Harris, CFAOwned
biotechnologypharmaceutical
BUY
They make medical devices. They bought a medical company focused on hands. Again demographics will increase demand for knee and hip replacements. Also, doctors seldom change device-makers, so they will stick with Stryker. They have little presence outside the U.S. so there are opportunities for growth there. Also, there's a backlog in elective surgeries.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 12/21, Down 4%) Elective surgeries shut down due to Covid, so now there's a backlog. Supply chain issues. Employment issues. They can get through these headwinds. Acquisition and integration going well. Digitization being integrated into services, including valuable patient data.
Paul Harris, CFAOwned
biotechnologypharmaceutical
HOLD
Robotic-assisted surgery has been a large growth area. Multiple compressed significantly. Elective surgeries accelerating, a positive for the business. Shipping and specialty metal constraints are priced in. Fairly priced. Hold through volatility. Quality company, well run. Look at ROE and ROE growth. Aim for a PE multiple of 21x.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Apr 06/21, Up 13%) Couple of tough years with Covid. Huge backlog, demographic tailwinds, improve people's quality of life. Pre-eminent company in this area. Can upsell new products coming out.
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Mar 29/21, Up 10%) Company was impacted by Covid-19 (elective procedures reduced).
As pandemic recedes, business will improve.
Expecting, A&D, further acquisitions and continued growth.
Trading at 26x earnings (P/E) which is a fair valuation.
Would buy more shares and hold.
biotechnologypharmaceutical
TOP PICK
Pandemic cancelled elective surgeries, backlog now clearing. Population is aging, and surgeries benefit quality of life. Brand loyalty among physicians. Geographical growth. Recent acquisition will increase digitization of products, which will help patient care. Will see uptick in revenue. Great valuation here. Yield is 1.06%. (Analysts’ price target is $281.30)
Paul Harris, CFAOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Feb 11/21, Up 4%) Came under pressure, as it's classified higher growth. Still likes their business, as everything in those operating rooms is made by Stryker. Main area of growth is robotic surgery. Wage and cost inflation. Sees perhaps slower capex. Very well run.
Paul MacDonaldOwned
biotechnologypharmaceutical
TOP PICK
73% of their business is in the US plus 21% in developed markets and 6% in emerging, so there's more EM growth to come. Also, elective surgeries were put on hold during Covid, so there's a big backlog to come. Also aging demographics are a tailwind. Also, surgeons remain loyal to their surgical products. (Analysts’ price target is $284.10)
Paul Harris, CFAOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Joint replacements and instrumentation business. Has come back in the latest rally. Good operators, but struggle for space in the operating room. Until that resolves, he'd shy away.